Nafamostat mesilate negatively regulates the metastasis of triple-negative breast cancer cells

Keyphrases

• Negatively Regulate 100%
• Metastasis 100%
• Triple-negative Breast Cancer Cells 100%
• Nafamostat Mesylate 100%
• Triple-negative Breast Cancer 50%
• Breast Cancer Cells 25%
• MDA-MB-231 Cells 25%
• Inhibitory Effect 12%
• Cell Growth 12%
• Tumor 12%
• Chemotherapy 12%
• Gene Expression 12%
• Cyclin-dependent Kinase 1 (CDK1) 12%
• Phosphorylation 12%
• Progesterone Receptor 12%
• Cell Cycle Arrest 12%
• Proliferation Migration 12%
• Cancer Progression 12%
• Treatment Options 12%
• Signaling Molecules 12%
• Poor Prognosis 12%
• Estrogen Receptor 12%
• Metalloproteinases 12%
• Anticancer Effect 12%
• Serine Protease Inhibitor 12%
• Transcription Factor Activity 12%
• Breast Tumor 12%
• Conventional Chemotherapy 12%
• Human Epidermal Growth Factor Receptor 2 (HER2) 12%
• ERK Activity 12%
• M Phase 12%
• Extracellular Environment 12%
• Metastasis-related Genes 12%
• Gene Downregulation 12%
• Smad2 Phosphorylation 12%
• Inhibits Proliferation 12%
• Breast Cancer Treatment 12%
• Treatment Efficacy 12%
• Safe Drugs 12%
• Breast Cancer Growth 12%
• Malignant Disease 12%
• Cell Metastasis 12%
• Adjunct Therapy 12%
• Pivotal Mechanism 12%
• Tumor Resistance 12%
• Short-term Response 12%
• Response Limits 12%
• Breast Cancer Lung Metastasis 12%
• Multitarget Drugs 12%

Medicine and Dentistry

• Cancer Cell 100%
• Metastatic Carcinoma 100%
• Triple Negative Breast Cancer 100%
• Nafamstat Mesilate 100%
• Breast Cancer 25%
• Chemotherapy 25%
• Neoplasm 12%
• Disease 12%
• Malignant Neoplasm 12%
• Transcription Factors 12%
• Gene Expression 12%
• Downregulation 12%
• Signaling Molecule 12%
• Metalloproteinase 12%
• Serine Proteinase Inhibitor 12%
• Cell Growth 12%
• Combination Therapy 12%
• Cancer Therapy 12%
• Adjuvant Therapy 12%
• Progesterone Receptor 12%
• Mitosis 12%
• Estrogen Receptor 12%
• Cancer Growth 12%
• Epidermal Growth Factor Receptor 12%
• Lung Metastasis 12%
• Cell Cycle Arrest 12%
• Cell Cycle Checkpoint 12%
• Cyclin-Dependent Kinase 1 12%
• Tumor Resistance 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Triple Negative Breast Cancer 100%
• Nafamstat Mesilate 100%
• Breast Cancer 25%
• Chemotherapy 25%
• Neoplasm 12%
• Malignant Neoplasm 12%
• Disease 12%
• Cyclin Dependent Kinase 1 12%
• Epidermal Growth Factor Receptor 12%
• Transcription Factors 12%
• Combination Therapy 12%
• Lung Metastasis 12%
• Estrogen Receptor 12%
• Serine Proteinase Inhibitor 12%
• Cancer Growth 12%
• Metalloproteinase 12%
• Progesterone Receptor 12%
• Tumor Resistance 12%